Aduhelm

Biogen is abandoning its lackluster Alzheimer’s disease drug, Aduhelm. The Massachusetts-based company announced Wednesday that it is pulling the medication from the market following poor sales and controversy over its approval by the Food and Drug Administration in 2021. The company says it is only doing so to “reprioritize” its resources toward its other, less contentious Alzheimer’s treatments, such as Leqembi.Lisa Frankenstein's Crew on Casting the Right Stars Adulhelm was developed by Biogen in conjunction with the…

The Biogen headquarters in Cambridge, Massachusetts, on Oct. 24, 2023.Vanessa Leroy | Bloomberg | Getty ImagesBiogen on Wednesday said it will discontinue the sale and development of its older and highly controversial Alzheimer's drug Aduhelm to refocus the company's efforts to treat the memory-robbing disease. The biotech company will focus on rolling out Leqembi, a newly approved Alzheimer's drug it developed with Japanese drugmaker Eisai. It also plans to work on a slate of experimental treatments for the disease.…

On Thursday, the Food and Drug Administration made a decision that’s likely to have a major impact on the landscape of Alzheimer’s disease research. The agency issued a full-throated traditional approval of the drug Leqembi, developed by the companies Eisai and Biogen. The drug is the first of its class to receive such approval and is intended to slow down the progression of the neurodegenerative disease.Will We See More of Uhura's Relationship with Spock? | io9 InterviewLeqembi is one of several antibody-based drugs that…

New clinical trial data released by Eli Lilly on Wednesday has provided the most promising results of any potential Alzheimer’s disease treatment yet. In a randomized, double-blinded, controlled phase III trial, the experimental drug donanemab significantly slowed cognitive decline in patients compared to placebo, with nearly half of those on the drug experiencing no decline at all a year later. The findings will likely pave the way for approval by the Food and Drug Administration, though the drug appears to carry a risk…

U.S. Food and Drug Administration Commissioner Robert Califf defended his agency’s decision to approve the Alzheimer’s drug Aduhelm, after an investigation by House Democrats found close cooperation between the drug’s sponsor and regulators. Findings released late last year from the then-Democratic-led Oversight and Reform Committee and the Energy and Commerce Committee faulted the FDA for holding an unusual number of meetings with Biogen Inc. while it weighed…

Image: Shutterstock (Shutterstock)The Food and Drug Administration on Friday granted the conditional approval of a new treatment for people with early Alzheimer’s disease: the antibody-based drug lecanemab, jointly developed by the pharmaceutical companies Biogen and Eisai. In a large trial, lecanemab appeared to slow down patients’ cognitive decline relative to those on placebo. But some experts and consumer advocates have questioned the drug’s safety and real-world value.Lecanemab works by targeting amyloid beta, a…